The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Pharmacodynamic (PD) assessment of blood pressure (BP) in a randomized dose-ranging trial of sorafenib (S).
M. L. Maitland
Consultant or Advisory Role - Abbott Laboratories; Pfizer (I); Takeda
Honoraria - Bayer
Research Funding - Bayer; Bristol-Myers Squibb; EMD Serono
T. Karrison
No relevant relationships to disclose
G. L. Bakris
Research Funding - Forest Laboratories; GlaxoSmithKline; Novartis
K. Fox
No relevant relationships to disclose
L. A. Janisch
No relevant relationships to disclose
S. Karovic
No relevant relationships to disclose
M. R. Levine
No relevant relationships to disclose
L. House
No relevant relationships to disclose
J. J. Wright
No relevant relationships to disclose
E. E. Cohen
No relevant relationships to disclose
G. F. Fleming
No relevant relationships to disclose
T. Y. Seiwert
No relevant relationships to disclose
V. M. Villaflor
Stock Ownership - Abbott Laboratories (B); Amgen (B); Bristol-Myers Squibb (B); Pfizer (B)
W. M. Stadler
Consultant or Advisory Role - Bayer; Genentech; Novartis; Pfizer
Research Funding - Bayer; Genentech; Novartis; Pfizer
M. J. Ratain
Consultant or Advisory Role - Abbott Laboratories; Bristol-Myers Squibb; Genentech; Onyx; Pfizer; Roche; Takeda
Honoraria - AstraZeneca
Research Funding - Bayer; Bristol-Myers Squibb